Study Links Paclitaxel To Lower-Leg Amputations
Executive Summary
New research links the use of stents and balloons coated with the drug paclitaxel to an increased risk of lower-leg amputation shortly following surgery. The study was conducted by Greek researcher Konstantinos Katsanos, who previously found an increased mortality risk in paclitaxel-treated patients.
You may also be interested in...
Boston Scientific Is Counting On COVID-19 Vaccine To Rebound In 2021
The company expects revenues across its businesses to rapidly return to their pre-pandemic growth rates in the second half of 2021.
Start-Up Spotlight: Efemoral Begins Trial Of Peripheral Stent With Inter-Scaffold Gaps
The EFEMORAL I trial is the first-in-human study of the start-up company’s FlexStep technology in patients with symptomatic femoropopliteal artery disease.
VIVA 2019: New Paclitaxel Data Shows Consistent Mortality Signal, No Clear Cause
Research investigating outcomes in patients treated with paclitaxel-coated devices demonstrated a consistent if modest mortality signal when compared to bare-metal stents. However, the signal was not seen in real-world data, and some researchers question whether the signal might stem from problems in the original trials.